Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human PRAME Antibodies:
Go to our pre-filtered search.
Human Polyclonal PRAME Primary Antibody for EIA, WB - ABIN453177
Rezvani, Yong, Tawab, Jafarpour, Eniafe, Mielke, Savani, Keyvanfar, Li, Kurlander, Barrett: Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. in Blood 2009
Show all 3 references for ABIN453177
Cow (Bovine) Polyclonal PRAME Primary Antibody for WB - ABIN2786466
Sakakura, Kubo, Ako, Ikeda, Funayama, Hirahara, Sugawara, Yasu, Kawakami, Momomura: Determinants of in-hospital death and rupture in patients with a Stanford B aortic dissection. in Circulation journal : official journal of the Japanese Circulation Society 2007
Show all 2 references for ABIN2786466
Human Polyclonal PRAME Primary Antibody for WB - ABIN2786465
Roman-Gomez, Jimenez-Velasco, Agirre, Castillejo, Navarro, Jose-Eneriz, Garate, Cordeu, Cervantes, Prosper, Heiniger, Torres: Epigenetic regulation of PRAME gene in chronic myeloid leukemia. in Leukemia research 2007
the expansion of the PRAME family occurred in both autosomes and sex chromosomes
PRAME expression is considered as a poor prognostic parameter in HL.
PRAME immunoreactivity in myeloid leukemia (show BCL11A Antibodies) (ML) of Down syndrome (DS) is largely due to the non-blast components, while PRAME immunoreactivity in blasts of Transient abnormal myelopoiesis (TAM (show CCNA1 Antibodies)) is not restricted to cases that progress to ML of DS.
This study shows the prognostic significance of PRAME expression in diffuse large B-cell lymphoma patients treated with R-CHOP (show DDIT3 Antibodies) therapy.
results suggested that PRAME was a predictor for better outcome, could be a useful target for immunotherapy, and might represent a candidate marker for the monitoring of minimal residual disease
elevated PRAME expression in head and neck squamous cell carcinoma
PRAME and WT1 (show WT1 Antibodies) transcripts constitute a good molecular marker combination for monitoring minimal residual disease in MDS (show PAFAH1B1 Antibodies).
PRAME impairs differentiation and increases proliferation likely via blocking retinoic acid receptor (show RARA Antibodies) signaling.
PRAME expression in leukaemic cell lines is upregulated by IFN gamma (show IFNG Antibodies) and LPS (show IRF6 Antibodies), suggesting a possible role in immune responses. PRAME associates with Elongin BC complexes by binding Elongin C (show TCEB1 Antibodies), and co-localises to the Golgi network. Nuclear PRAME interacts with Histone H3 (show HIST3H3 Antibodies). The results suggest that PRAME has dual roles in gene regulation in the nucleus and protein turnover trafficking in the Golgi
The complex PRAME/EZH2 (show EZH2 Antibodies) is able to repress TRAIL expression, in a cancer-specific manner; inhibition of PRAME/EZH2 (show EZH2 Antibodies) releases apoptosis-mediating TRAIL. (Review)
Knock-down of PRAME increases retinoic acid signaling and cytotoxic drug sensitivity of Hodgkin lymphoma cells.
This gene encodes an antigen that is predominantly expressed in human melanomas and that is recognized by cytolytic T lymphocytes. It is not expressed in normal tissues, except testis. This expression pattern is similar to that of other CT antigens, such as MAGE, BAGE and GAGE. However, unlike these other CT antigens, this gene is also expressed in acute leukemias. Five alternatively spliced transcript variants encoding the same protein have been observed for this gene.
preferentially expressed antigen in melanoma
, Opa-interacting protein OIP4
, cancer/testis antigen 130
, melanoma antigen preferentially expressed in tumors
, opa-interacting protein 4
, preferentially expressed antigen of melanoma